

1 **Title: “Effectiveness of COVID-19 Vaccines in preventing**  
2 **Infectiousness, Hospitalization and Mortality: A Historical Cohort**  
3 **Study Using Iranian Registration Data During Vaccination program”**

4 **Running Title: “COVID-19 vaccines effectiveness in Iran”**

5 **Alireza Mirahmadizadeh<sup>†</sup>, Alireza Heiran<sup>†</sup>, Kamran Bagheri Lankarani, Mohammadreza Serati,**  
6 **Mohammad Habibi, Owrang Eilami, Fatemeh Heiran, Mohsen Moghadami<sup>‡</sup>**

7 **Author affiliations:** Non-communicable Diseases Research Center, Shiraz University of Medical  
8 Sciences, Shiraz, Iran (A. Mirahmadizadeh, A. Heiran, M. Moghadami); Health Policy Research  
9 Center, Shiraz University of Medical Sciences, Shiraz, Iran (K. Bagheri L., M. Moghadami);  
10 Statistics and Information Technology Management, Shiraz University of Medical Sciences,  
11 Shiraz, Iran (M. Serati, M. Habibi); Shiraz University of Medical Sciences, Shiraz, Iran (O. Eilami);  
12 Medis Holding, Shiraz, Iran (F. Heiran); University of Isfahan, Isfahan, Iran (F. Heiran).

13 <sup>†</sup> These first authors contributed equally to this article.

14 <sup>‡</sup> **Corresponding author:** Mohsen Moghadami, Health Policy Research Center, School of  
15 Medicine, Shiraz University of Medical Sciences, Zand Ave., Shiraz, Iran. PO: 71348-45794, Tel.:  
16 +987132309615, Fax: +987132309615-116, Email: moghadami@sums.ac.ir, ORCID: 0000-0001-  
17 8015-0313

18 **Alternate author:** Alireza Heiran, M.D., Non-communicable Diseases Research Center, Shiraz  
19 University of Medical Sciences, Shiraz, Iran. PO: 7193635899; Tel.: +987136122302; Fax:  
20 +987136122302; Mobile Tel.: +989178326026. E-mail: heiran.alireza@gmail.com, ORCID: 0000-  
21 0001-6567-530

22 **Key points:** The mass vaccination program with implementing a group of vaccines, that even for  
23 some of them (rAd26-rAd5, and BIV1-CovIran vaccines) have been only regionally authorized  
24 for emergency use, has been associated with a dramatic reduction in documented COVID-19  
25 infection, as well as in hospitalization and deaths related to the COVID-19 diagnosis.

26  
27  
28  
29  
30  
31

32 **Abstract**

33 **Background:** There are some concerns about the effectiveness of the inactivated and vector-  
34 based vaccines against SARS-CoV-2 in the real-world settings with the emergence of new  
35 mutations, especially variants of concern. Data derived from administrative repositories during  
36 mass-vaccination campaigns or programs are of interest to study vaccine effectiveness (VE).

37 **Methods:** Using 4-repository administrative data linkage, we conducted a historical cohort  
38 study on a target population of 3,628,857 inhabitants aged at least 18 years residing in  
39 Southern Iran.

40 **Results:** We estimated 71.9% [95% CI: 70.7-73.1%], 81.5% [95% CI: 79.5-83.4%], 67.5% [95% CI:  
41 59.5-75.6%], and 86.4% [95% CI: 84.1-88.8%] hospitalization reduction for those who received  
42 the full vaccination schedule of BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran  
43 vaccines, respectively. A high reduction in mortality – at least 85% – was observed in all age  
44 subgroups of fully immunized population.

45 **Conclusion:** The pragmatic implementation of a vaccination plan including all available vaccine  
46 options in the Iranian population was associated with a significant reduction in documented  
47 COVID-19 infection, hospitalization, and death associated with COVID-19.

48 **Keywords:** COVID-19; SARS-CoV-2; COVID 19 Vaccines; Vaccine; Effectiveness; Real-world;  
49 Cohort.

50

51

52

53

54

55

56

57

58

59

60

## 61 Text

### 62 1- Introduction

63 Many mass-vaccination campaigns or programs are currently underway in all around the world  
64 to curb the spread of SARS-CoV-2. In the Islamic Republic of Iran, vaccination was initially  
65 started for immunocompromised patients, older people and health workers on February 9,  
66 2021, with rAd26-rAd5 (Gam-COVID-Vac, Sputnik V). Subsequently, vaccination program was  
67 expanded with the other COVID-19 vaccines authorized by the Iranian ministry of health,  
68 including BBIBP-CorV vaccine (Sinopharm) and ChAdOx1-S/nCoV-19 vaccine (AZD1222, Oxford–  
69 AstraZeneca) <sup>[1-3]</sup> with coverage of persons in clinical risk groups and younger-age cohorts,  
70 followed by entire population above 12 years old. As of October 22, 2021, a total of 78,665,265  
71 COVID-19 vaccine doses has been administrated nationally. Controlled clinical trials and real-  
72 world clinical studies from some countries have yielded clear evidence of the effectiveness of  
73 the just-mentioned vaccines <sup>[4-6]</sup>.

74 However, with the emergence of new mutations, especially variants of concern (VOC), there are  
75 some debates against the protective effects of the vaccines. Laboratory findings indicate that  
76 serum samples from vaccinated persons have been attenuated for the neutralization effects  
77 against the B.1.351 (beta) variant <sup>[7,8]</sup>. Moreover, observational data from Qatar showed a  
78 modestly reduced effectiveness against symptomatic infection caused by beta variant but still  
79 high levels of effectiveness against severe, critical, or fatal disease amongst people vaccinated  
80 with the BNT162b2 vaccine (Pfizer–BioNTech) <sup>[9]</sup>. The delta variant is characterized by some  
81 new mutation on the spike protein <sup>[10]</sup>. Some of these mutations might affect immune  
82 responses focused toward the key antigenic regions of receptor-binding protein and S1–S2  
83 cleavage site. It appears that strains with mutations at this specific location can increase  
84 replication, leading to increased replication transmission and higher viral loads <sup>[11]</sup>. Therefore,  
85 there are some concerns about the effectiveness of the available vaccine in the real-world  
86 settings with widespread distribution of delta variant. For example, researchers demonstrated  
87 an accelerated decline in protection against SARS-CoV infection by the fourth month after  
88 vaccination. Or, effectiveness has been reached low levels of approximately 20% by the seventh  
89 month after the second dose of the BNT162b2 vaccine <sup>[12]</sup>.

90 In this study, we sought to estimate the effectiveness of the four mostly used vaccines in the  
91 Iranian national vaccination program against SARS-CoV-2, rAd26-rAd5, ChAdOx1-S/nCoV-19,  
92 BBIBP-CorV, and BIV1-CovIran (COVIran Barekat) against infection, hospitalization, and death  
93 caused by the circulating variants from February till late October in the country.

### 94 2- Materials and Methods

#### 95 2-1- Study Design, Population and Data Repositories

96 As a potential spin-off of administrative data linkage, we conducted a historical cohort study on  
97 the individual data of a target population of 3,628,857 (out of 4,943,933) inhabitants aged at  
98 least 18 years residing in the regions under cover of the Shiraz University of Medical Sciences  
99 (SUMS), Fars province, Southern Iran, from the start of the vaccination program (February 09,  
100 2021) to the end of follow-up (October 22, 2021). This study followed the Strengthening the  
101 Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Biomedical  
102 Research Ethics Committees of Shiraz University of Medical Sciences gave ethical approval for  
103 this work (code = IR.SUMS.REC.1400.486) (supplementary file).

104 By using recoded national ID as the join variable, four data repositories were combined. All data  
105 were limited to the population under cover of SUMS, which is in charge of vaccination program,  
106 COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) tests, COVID-19  
107 hospitalization, COVID-19 outcome registry, and health data documentation.

108 [1] The first repository was the “Integrated Health System” (SIB, In Persian: “Samaneh  
109 Yekparche-ye Behdashti”) – an electronic health record (EHR) system established 5 years ago –  
110 that by the start of vaccination program was introduced with the vaccination data. This  
111 repository includes demographic characteristics (i.e., sex and age), address, and type, dose and  
112 data of the administered vaccine. The 4 vaccines studied against COVID-19 were [1] the BBIBP-  
113 CorV vaccine, which is a monovalent Vero cells vaccine composed of inactivated 19nCoV-CDC-  
114 Tan-HB02 (HB02) strain of SARS-CoV-2 virus antigens.<sup>[13]</sup>; [2] the ChAdOx1-S/nCoV-19 vaccine,  
115 which is a modified rAd vector (ChAdOx1), containing the full-length codon-optimized coding  
116 sequence of the spike protein of SARS-CoV-2 (ChAdOx1-S/nCoV-19), with a tissue plasminogen  
117 activator leader sequence<sup>[14]</sup>; [3] the rAd26-rAd5, which is a recombinant replication-deficient  
118 adenovirus (rAd)-based vaccine, containing rAd type 26 (rAd26) and rAd type 5 (rAd5) vectors  
119 that both of them carry the gene for SARS-CoV-2 full-length glycoprotein S (rAd26-S and rAd5-S)  
120<sup>[2]</sup>; and [4] the BIV1-CovIran (COVIran Barekat), which is an inactivated whole-virus SARS-CoV-2  
121 vaccine<sup>[15]</sup>. The first two vaccines have been authorized for emergency use by WHO, while the  
122 other two vaccines have been listed for emergency use, regionally, so far.

123 [2] The second repository was “CORONALAB” that contains the data of all people who  
124 underwent a COVID-19 RT-PCR test in public or private centers by the beginning of COVID-19  
125 pandemic. Through this dataset, definite cases of COVID-19 infection were identified. This  
126 repository includes demographic characteristics, RT-PCR sampling date (equivalent to date of  
127 COVID-19 infection, if positive) and result, occupation (especially being a health worker),  
128 underlying medical condition (i.e., pregnancy, diabetes mellitus, malignancy, hypertension,  
129 cardiovascular disease, chronic kidney disease, and pulmonary disease), presenting sign and  
130 symptoms (i.e., nausea, diarrhea, generalized body pain, dyspnea, cough, and fever), and if a  
131 subject was hospitalized or not.

132 [3] The Third repository was hospitals' "Medical Care Monitoring Center" (MCMC); that is,  
133 during COVID-19 pandemic was introduced with recording data about all suspected  
134 hospitalizations (Gray Zones admissions) due to COVID-19 as well as between-the-wards and -  
135 hospitals transfers. The acquired dataset includes admission data, underlying medical condition,  
136 presenting sign and symptoms, inpatient RT-PCR result, ward and hospital transfers' date,  
137 outcome, and outcome data.

138 [4] The last repository was department of health's "Registry of Deaths", which served to  
139 recheck the MCMC outcome data. In addition, this was used as an adjacent dataset to add  
140 people who died within 30 days of an admission related to COVID-19 diagnosis but their data  
141 were missed in MCMC dataset. To these ends, unofficial monthly datasets were made available  
142 with a 10-day delay for research purposes, and we specifically searched for U07.1 (denoting  
143 COVID-19, virus identified) and U07.2 (denoting COVID-19, virus not identified) ICD-10 codes  
144 with date of death <sup>[16]</sup>. Moreover, several other overlapping variables were rechecked using the  
145 just-mentioned repositories, including [1] demographics (using all four repositories), [2]  
146 hospitalization (using CORONALAB and MCMC), and [3] RT-PCR result (using CORONALAB and  
147 MCMC).

## 148 **2-2- Data Processing and Outcomes**

149 The assessed outcomes were the incidence density ( $\text{count}_{\text{event}}/100,000 \text{ persons-day}$ ) of [1]  
150 COVID-19 infection confirmed by RT-PCR, [2] hospitalization from suspicious or confirmed  
151 COVID-19 infection lasting more than 24 hours, [3] RT-PCR-confirmed hospitalization from  
152 COVID-19, [4] death in hospital from suspicious or confirmed COVID-19 infection, [5] and RT-  
153 PCR-confirmed death in hospital from COVID-19.

154 Subjects who had multiple RT-PCR tests were treated in two different ways: [1] for those who  
155 had "serial" tests (e.g., subjects who required a negative result for return to works), date of the  
156 first positive test was recorded; [2] for those who had "sporadic" tests, date of all positive tests  
157 were recorded. Furthermore, hospitalization with length of stay (LoS) less than 24 hours as well  
158 as hospital readmissions within 30 days after discharge were ignored.

159 A subject was excluded if [1] aged <18 years at initiation of vaccination program ( $n =$   
160  $1,315,076$ ), [2] had previous COVID-19 infection (either positive RT-PCR test or being  
161 symptomatic), hospitalization or death prior to the initiation of vaccination program or before  
162 14 days after receiving the second dose ( $n = 81,069$ ), [3] their first follow-up day (index date) –  
163 which was 14 days after the second dose date – would be beyond the end of follow-up  
164 (October 22, 2021) ( $n = 955,393$ ), [4] did not receive the second dose of vaccine ( $n = 585,608$ ),  
165 [5] was not vaccinated with two doses of an identical vaccine ( $n = 11,226$ ), [6] vaccinated with  
166 uncommon vaccines ( $n = 2,304$ ), and [7] received the third dose of a vaccine ( $n = 3,908$ ). It

167 should be noticed that 107,201 subjects were also excluded due to unreliable data, i.e., missing  
168 or misleading vaccination date and duplicated data.

169 Subjects defined as vaccinated if [1] received two doses of an identical vaccine and [2] their  
170 index date was before the end of follow-up (October 22, 2021). In each vaccinated subject,  
171 persons-day was calculated by subtracting the index date from the date of censoring day, which  
172 was the occurrence date of any of the aforementioned events or, if no event was developed,  
173 the last day of follow-up (October 22, 2021).

174 In unvaccinated people, persons-day was calculated by subtracting index date (March 23, 2021;  
175 42 days [assuming 4 weeks of between-doses interval + 14 days after second dose was injected]  
176 after the start of the vaccination program) from the occurrence date of any of the  
177 aforementioned events. Similar to the vaccinated group, unvaccinated people who did not  
178 develop any event, were assumed to be alive and the date of data censoring was set as October  
179 22, 2021. Importantly, according to the Iranian notional wide vaccination program, BBIBP-CorV,  
180 rAd26-rAd5 and BIV1-CovIran vaccines required two doses separated by an interval of at least 4  
181 weeks; but this interval was 3 months for ChAdOx1-S/nCoV-19 vaccine. Hence, for assessing the  
182 effectiveness of just-mentioned vaccine, the index date of unvaccinated cohort was set to May  
183 24, 2021 (matched risk period).

### 184 **2-3- Statistical Analysis**

185 The R programming language (version 4.0.4 for MacOS) was used for statistical analysis, and its'  
186 package "tidyverse" was utilized for data combination and data cleaning to yield an analysis-  
187 ready dataset.

188 To calculate vaccine effectiveness, relative risk (RR) values (with [95% confidence interval (CI)])  
189 were subtracted from 1. We utilized the aggregated persons-day as denominator of the relative  
190 risk calculation fraction (Box 1), which is expected to correct for differences in exposure (follow-  
191 up) times, adjust for heterogenous "risk periods" (varying dynamic of a pandemic, change in  
192 dominant variants, as well as, the fact of more vaccinated people, less burden of disease), and  
193 consider the time intervals for those who developed an event, which were censored before the  
194 end of study. The confidence interval of each RR value was calculated based on the  
195 approximate procedures proposed by Ederer and Mantel<sup>[17]</sup> (Table 1).

196 Also, vaccine effectiveness was reported in different age groups (18-44, 45-64 and >64 years),  
197 separately. For this analysis, the unvaccinated cohort was selected from the same age group.  
198 Finally, the incidence density per each 100,000 persons-day of follow-up was reported. For this  
199 purpose, the "PersonTime[1] module" of "Open Source Epidemiologic Statistics for Public  
200 Health" (Open Epi) was used to calculate persons-day [95% CI] through "Mid-P exact test" with  
201 Miettinen's modification<sup>[19]</sup>.

### 202 **3- Results**

203 Among 1,882,148 adults (mean age:  $46.74 \pm 17.51$  years; 916,904 [48.72%] female) who  
204 composed the analysis-ready dataset, 881,638 (46.84%) were vaccinated with two doses and  
205 considered immunized, from February 09, 2021 to October 22, 2021. The mean ages were  
206  $53.39 \pm 15.98$  and  $40.80 \pm 16.66$  years, and 369,274 (41.88%) and 547,630 (54.74%) were  
207 female in the vaccinated and unvaccinated cohorts, respectively. The vaccines composition was  
208 75.33% for BIBP-CorV (n = 664,101), 14.87% for ChAdOx1-S/nCoV-19 (n = 131,102), 1.62% for  
209 rAd26-rAd5 (n = 14,273), and 8.18% for BIV1-CovIran (n = 72,162).

210 Amongst 948,230 people aged 18-44 years, 259,949 (27.41%) received 2 doses of a vaccine.  
211 Amongst 585,166 people aged 45-64 years, 393,994 (67.33%) received 2 doses of a vaccine.  
212 And, amongst 348,752 people aged 65 years and older, 227,695 (65.29%) received 2 doses of a  
213 vaccine.

214 The incidence density of confirmed COVID-19 was 20.5 [95% CI: 20.3-20.7] cases/100,000  
215 persons-day among the unvaccinated, and 4.12 [95% CI: 4.02-4.22], 3.49 [95% CI: 3.30-3.70],  
216 5.19 [95% CI: 4.47-5.99], and 2.64 [95% CI: 2.41-2.88] cases/100,000 persons-day among those  
217 who fully immunized with BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran  
218 vaccines, respectively. These yielded 79.9% [95% CI: 79.4-80.4%], 84.4% [95% CI: 83.5-85.3%],  
219 74.7% [95% CI: 71.0-78.4%], and 87.1% [95% CI: 86.0-88.3%] positive RT-PCR tests reduction  
220 rate for those who received the full vaccination schedule of BIBP-CorV, ChAdOx1-S/nCoV-19,  
221 rAd26-rAd5, and BIV1-CovIran vaccines, respectively (Table 2).

222 The incidence density of hospitalization with confirmed COVID-19 diagnosis was 5.34 [95% CI:  
223 5.24-5.45] cases/100,000 persons-day among the unvaccinated, and 1.50 [95% CI: 1.44-1.56],  
224 1.10 [95% CI: 0.99-1.22], 1.74 [95% CI: 1.35-2.21], and 0.73 [95% CI: 0.61-0.86] cases/100,000  
225 persons-day among those who fully immunized with BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-  
226 rAd5, and BIV1-CovIran vaccines, respectively. These yielded 71.9% [95% CI: 70.7-73.1%], 81.5%  
227 [95% CI: 79.5-83.4%], 67.5% [95% CI: 59.5-75.6%], and 86.4% [95% CI: 84.1-88.8%]  
228 hospitalization reduction for those who received the full vaccination schedule of BIBP-CorV,  
229 ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran vaccines, respectively (Table 2).

230 The incidence density of death with confirmed COVID-19 diagnosis was 0.95 [95% CI: 0.91-1.00]  
231 cases/100,000 persons-day among the unvaccinated, and 0.13 [95% CI: 0.12-0.15], 0.06 [95%  
232 CI: 0.04-0.09], 0.00, and 0.02 [95% CI: 0.00-0.04] cases/100,000 persons-day among those who  
233 fully immunized with BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran vaccines,  
234 respectively. These values were represented 86.1% [95% CI: 84.1-88.0%], 91.8% [95% CI: 88.2-  
235 95.4%], 100%, and 98.3% [95% CI: 96.3-100%] reduction in mortality for BIBP-CorV, ChAdOx1-  
236 S/nCoV-19, rAd26-rAd5, and BIV1-CovIran vaccines, respectively (Table 2).

237 In those who fully immunized with a vaccine, a high reduction in mortality (>95%) was observed  
238 in all age subgroups, except for 18-44 and >64 years age groups who received BIBP-CorV  
239 vaccine (87.3% [95% CI: 79.5-94.8%] and 86.3% [95% CI: 84.1-88.4%]). In addition, rate of  
240 reduction in hospitalization was noticeably lower in elderly (>64 years age group); that is, full  
241 vaccination schedule with BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran  
242 vaccines, reduced hospitalization for 45.7% [95% CI: 42.1-49.2%], 76.0% [95% CI: 73.0-78.9%],  
243 45.5% [95% CI: 4.9-85.8%], and 80.3% [95% CI: 72.8-87.8%], respectively. Furthermore,  
244 specifically, for the people aged >64 years, the full schedule by BIBP-CorV, ChAdOx1-S/nCoV-19,  
245 rAd26-rAd5, and BIV1-CovIran vaccines was associated with 29.1% [95% CI: 25.3-32.8%], 62.4%  
246 [95% CI: 59.0-65.6%], 76.3% [95% CI: 53.1-99.5%], and 67.0% [95% CI: 58.5-75.4%] reduction in  
247 infection (Table 3).

248 Total and age-specific frequency of events, as well as age-specific incidence density per 100,000  
249 persons-day, are yielded in supplementary file.

#### 250 **4- Discussion**

251 Besides proving vaccine efficacy in clinical trials, demonstrating vaccine effectiveness (VE) in  
252 real-world settings has an essential role in strategic planning and controlling infectious diseases  
253 in the community. For various COVID-19 vaccines, there are a lot of data about efficacy<sup>[20-23]</sup>.  
254 There is, to our knowledge, no VE assessment is conducted on the real-world big-data of the  
255 inactivated and vector-based vaccines that are utilizing in Islamic Republic of Iran.

256 In a context of vaccine shortages for our country, related to many factors (i.e., supply delays,  
257 sanctions, etc.), this study found that the mass vaccination program with implementing a group  
258 of vaccines that even for some of them (rAd26-rAd5, and BIV1-CovIran vaccines) there is limited  
259 information for effectiveness and impact, has been associated with a dramatic reduction in  
260 documented COVID-19 infection, as well as in hospitalization and deaths related to the COVID-  
261 19 diagnosis. This information is of health relevance and encourages health authorities to  
262 rapidly reach a critical mass of vaccinated population to control the disease over the country.

263 Our findings demonstrated high VE against laboratory-confirmed SARS-CoV-2 infection after  
264 receiving the second doses of all used vaccine. The VE point estimates reached 87.1%, with  
265 BIV1-CovIran, and at least around 75% with rAd26-rAd5. Our results consistently indicate that a  
266 high level of protection, with little variability, has been provided by all available vaccines against  
267 COVID-19 after the second dose of vaccine in the Islamic Republic of Iran. The VE estimates are  
268 consistent with the vaccine efficacy results published by the other researchers and original  
269 vaccine research groups<sup>[24-26]</sup>.

270 In our analysis of approximately 13,987 hospitalizations of adults with laboratory-confirmed  
271 COVID-19 during February 17–October 22, 2021, receipt of 2 doses of any type of authorized

272 vaccine was effective in preventing laboratory-confirmed COVID-19 hospitalizations among  
273 patients who were elderly (VE range = 45.5-80.3%) and those who were at younger age groups  
274 (VE range = 60.1-94.4% for 18-44-year-old age group, 76-95.2% for 45-64-year-old age group).  
275 Nonetheless, elderly was largely less protected from severe COVID-19 outcomes than younger  
276 age groups, supporting the WHO's recommendation for administering the booster dose of a  
277 vaccine to enhance further protection, especially in elderly persons, against severe COVID-19  
278 outcomes <sup>[28]</sup>.

279 The analysis found significant protection associated with two doses of any of the vaccines used  
280 to prevent death from any cause. However, compared with the other used vaccines, the BBIBP-  
281 CorV vaccine was associated with a higher mortality risk during follow-up. The reasons why two  
282 doses of BBIBP-CorV were rather associated with lower protection against death than other  
283 studied vaccines remain obscure. One can explain that the low effectiveness found in people  
284 received inactivated whole virus vaccines should not be surprising, since the process of  
285 treatment used to eliminate infectivity may be effectively damaging to modify immunogenicity,  
286 especially of the antigens needed to induce cell-mediated immune responses. Additionally, it  
287 should be emphasized that although there was no large difference in the mortality among the  
288 populations that received the different types of vaccines in our study, this should be evaluated  
289 in the future studies, involving more numbers of cases – especially the other three vaccines –  
290 and other parts of the country to confirm if there is different effectiveness among these  
291 vaccines.

292 The findings in our study are subject to at least four limitations. First, vaccination status and  
293 outcome misclassifications might be plausible, comparing the vaccine efficacy studies, despite  
294 the high specificity of the COVID-19 vaccination status from our data repositories. Worth  
295 noting, we performed a number of data-recheck plans. Second, while our study covered a long  
296 follow-up period of 35 weeks, VE data with longer follow-up are warranted. Second,  
297 underestimation of actual SARS-CoV-2 infection among the study population might be  
298 happened due to the underuse of PCR tests for all suspected patients in the community. Third,  
299 noncomprehensive data entry – specifically, the COVID-19-related administrative data registries  
300 were not intended to collect the unvaccinated population data – for comorbidities and other  
301 confounding factors did not allow us to introduce these variables into the analysis. Fourth, due  
302 to lower numbers of vaccinated people with rAd26-rAd5 and BIV1-CovIran vaccines, VE values  
303 for these two vaccines might not be robust.

304 **Conclusion:** The present study shows that the pragmatic implementation of a vaccination plan  
305 including all different vaccine options in the Iranian population was associated with a significant  
306 reduction in documented COVID-19 infection, hospitalization, and death associated with  
307 COVID-19. These results suggest implementing mass vaccination strategies with these available

308 vaccines in the shortest possible time. Also, our findings are the first actual world report for an  
309 Iranian vaccine, BIV1-CovIran, with noticeable results and role in mass immunization goals.

310 **Conflicts of Interest:** No conflict of interest is declared by all authors.

311 **Funding:** This work was not financially supported.

312 **Data sharing statement:** The data repositories generated during the current study are not  
313 publicly available; however, would be available from the corresponding author on reasonable  
314 request to the Shiraz University of Medical Sciences, Vice Chancellor of Research.

315 **Contribution:** Conceptualization (A.M., A.H., K.B.L., M.M.); Data curation (M.S., M.H.); Formal  
316 analysis (A.M., O.E.); Methodology (A.H., A.M.); Project administration (A.H., F.H., M.M.);  
317 Software (A.H., F.H.); Supervision (A.M., K.B.L., M.M.); Validation (A.M., M.S., M.H.); Writing –  
318 original draft (A.H., M.M.); Writing – review & editing (K.B.L., O.E.).

## 319 5- References

- 320 1- Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2  
321 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A  
322 Randomized Clinical Trial. *JAMA*. 2021;326(1):35-45. doi: 10.1001/jama.2021.8565.
- 323 2- Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva  
324 AS, et al; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5  
325 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a  
326 randomised controlled phase 3 trial in Russia. *Lancet*. 2021;397(10275):671-681. doi:  
327 10.1016/S0140-6736(21)00234-8.
- 328 3- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al; Oxford COVID  
329 Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)  
330 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,  
331 South Africa, and the UK. *Lancet*. 2021;397(10269):99-111. doi: 10.1016/S0140-  
332 6736(20)32661-1.
- 333 4- Jahromi M, Al Sheikh MH. Partial protection of Sinopharm vaccine against SARS COV2  
334 during recent outbreak in Bahrain. *Microb Pathog*. 2021;158:105086. doi:  
335 10.1016/j.micpath.2021.105086.
- 336 5- Ahamed F, Ganesan S, James A, Zaher WA. Understanding perception and acceptance of  
337 Sinopharm vaccine and vaccination against COVID-19 in the UAE. *BMC Public Health*.  
338 2021;21(1):1602. doi: 10.1186/s12889-021-11620-z.
- 339 6- Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. *Lancet*.  
340 2021;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4.
- 341 7- Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2  
342 variants B.1.351 and B.1.1.7. *Nature*. 2021;593(7857):130-135.

- 343 8- Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. Neutralizing Activity of  
344 BNT162b2-Elicited Serum. *N Engl J Med.* 2021;384(15):1466-1468. doi:  
345 10.1056/NEJMc2102017.
- 346 9- Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination.  
347 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351  
348 Variants. *N Engl J Med.* 2021;385(2):187-189. doi: 10.1056/NEJMc2104974.
- 349 10- European Centre for Disease Prevention and Control. Emergence of SARS-CoV-2 B.1.617  
350 variants in India and situation in the EU/EEA– 11 May 2021. 2021 May 11 [cited 2021  
351 December 01]. [https://www.ecdc.europa.eu/en/publications-data/threat-assessment-](https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants)  
352 [emergence-sars-cov-2-b1617-variants](https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants)
- 353 11- Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, et al. Furin Cleavage  
354 Site Is Key to SARS-CoV-2 Pathogenesis. *bioRxiv* [Preprint]. 2020:2020.08.26.268854.  
355 doi: 10.1101/2020.08.26.268854.
- 356 12- Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.  
357 Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J*  
358 *Med.* 2021;385(24):e83. doi: 10.1056/NEJMoa2114114.
- 359 13- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an  
360 inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-  
361 controlled, phase 1/2 trial. *Lancet Infect Dis.* 2021;21(1):39-51. doi: 10.1016/S1473-  
362 3099(20)30831-8.
- 363 14- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety  
364 and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary  
365 report of a phase 1/2, single-blind, randomised controlled trial. *Lancet.*  
366 2020;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4.
- 367 15- Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E, et al. Safety and  
368 potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical  
369 study. *Rev Med Virol.* 2021:e2305. doi: 10.1002/rmv.2305.
- 370 16- World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak.  
371 [cited 2021 December 01]. [https://www.who.int/standards/classifications/classification-](https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak)  
372 [of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak](https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak)
- 373 17- Ederer F, Mantel N. Confidence limits on the ratio of two Poisson variables. *Am J*  
374 *Epidemiol.* 1974;100(3):165-167.
- 375 18- Szklo M, Nieto FJ. *Epidemiology: Beyond the Basics.* Fourth edition. Burlington,  
376 Massachusetts: Jones & Bartlett Learning. p490.
- 377 19- Dean AG, Sullivan KM, Soe MM. *OpenEpi: Open Source Epidemiologic Statistics for*  
378 *Public Health, Version 3.01.* 2013 April 06 [cited 2021 November 21].  
379 [https://www.openepi.com/Menu/OE\\_Menu.htm](https://www.openepi.com/Menu/OE_Menu.htm)

- 380 20- Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet*.  
381 2021;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4.
- 382 21- Holt SG, Mahmoud S, Ahmed W, Acuna JM, Al Madani AK, Eltantawy I, et al. An analysis  
383 of antibody responses and clinical sequelae of the Sinopharm HB02 COVID19 vaccine in  
384 dialysis patients in the United Arab Emirates. *Nephrology (Carlton)*.  
385 2021;10.1111/nep.13980. doi: 10.1111/nep.13980.
- 386 22- Montalti M, Soldà G, Di Valerio Z, Salussolia A, Lenzi J, Forcellini M, et al; San Marino  
387 Republic COVID ROCCA Group. ROCCA observational study: Early results on safety of  
388 Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active  
389 surveillance. *EClinicalMedicine*. 2021;38:101027. doi: 10.1016/j.eclinm.2021.101027.
- 390 23- Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Azimi E, Emamipour N, et al. Safety  
391 and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A  
392 Preclinical Study. *bioRxiv*. 2021.
- 393 24- Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et  
394 al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of  
395 Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-  
396 CoV-2 Variants. *Vaccines (Basel)*. 2021;9(7):779. doi: 10.3390/vaccines9070779.
- 397 25- Chagla Z. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19  
398 >14 d after the 2nd dose. *Ann Intern Med*. 2021;174(3):JC29. doi:  
399 10.7326/ACPJ202103160-029.
- 400 26- Siddique S, Ahmed S. COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and  
401 Availability. *Journal of Islamabad Medical and Dental College*. 2021;10(2):125-130.
- 402 27- World Health Organization. Interim statement on booster doses for COVID-19  
403 vaccination. 2021 October 04 [cited 2021 December 01].  
404 [https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-](https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination)  
405 [covid-19-vaccination](https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination)

406  
407  
408  
409  
410  
411  
412  
413

414  
415  
416  
417

**Table 1.** Relative risk formulas of incidence densities <sup>[18]</sup>

<p>1) <math>RR = \frac{\frac{Event_{vaccinated}}{Aggregated\ persons - day\ vaccinated}}{\frac{Event_{unvaccinated}}{Aggregated\ persons - day\ unvaccinated}}</math></p> <p>2) <math>95\% CI = Lower\ limit = \left[ \frac{P_L}{1 - P_L} \right] \times \frac{L_2}{L_1}; Upper\ limit = \left[ \frac{P_U}{1 - P_U} \right] \times \frac{L_2}{L_1}</math></p> <ul style="list-style-type: none"> <li>• <math>O_1 = events\ in\ vaccinated\ people</math></li> <li>• <math>O_2 = events\ in\ unvaccinated\ people</math></li> <li>• <math>L_1 = persons - day\ in\ vaccinated\ people</math></li> <li>• <math>L_2 = persons - day\ in\ unvaccinated\ people</math></li> <li>• <math>R_1 = event\ rate\ in\ vaccinated\ people\ (O_1/L_1)</math></li> <li>• <math>R_2 = event\ rate\ in\ unvaccinated\ people\ (O_2/L_2)</math></li> <li>• <math>\hat{P} = set\ limits\ on\ the\ ratio\ of\ events\ in\ vaccinated\ people = O_1/O_1 + O_2</math></li> <li>• <math>Lower\ (P_L)\ and\ Upper\ (P_U)\ limits\ of\ the\ 95\% CI = P_L = \hat{P} - \left[ 1.96 \times \sqrt{\frac{\hat{P}(1-\hat{P})}{O_1+O_2}} \right]; P_U = \hat{P} + \left[ 1.96 \times \sqrt{\frac{\hat{P}(1-\hat{P})}{O_1+O_2}} \right]</math></li> </ul>
---

418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430

431

432

**Table 2.** Incidence density per 100,000 persons-day and SARS-CoV-2 vaccine effectiveness regarding COVID-19 infection, hospitalization and death in the historical cohorts of fully vaccinated and unvaccinated people

Vaccine	Infection [Positive RT-PCR]	Hospitalization [suspicious/definite <sup>*</sup> ]	Hospitalization [definite]	Death [suspicious/definite]	Death [definite]
<b>Incidence density per 100,000 persons-day</b>					
BiBP-CorV	4.12 [4.02-4.22] <sup>§</sup>	2.27 [2.20-2.35]	1.50 [1.44-1.56]	0.17 [0.15-0.19]	0.13 [0.12-0.15]
ChAdOx1-S/nCoV-19	3.49 [3.30-3.70]	1.90 [1.76-2.05]	1.10 [0.99-1.22]	0.10 [0.07-0.13]	0.06 [0.04-0.09]
rAd26-rAd5	5.19 [4.47-5.99]	3.01 [2.48-3.61]	1.74 [1.35-2.21]	0.03 [0.00-0.13]	0.00 [-] <sup>‡</sup>
BiV1-CovIran	2.64 [2.41-2.88]	1.20 [1.05-1.37]	0.73 [0.61-0.86]	0.03 [0.00-0.06]	0.02 [0.00-0.04]
Unvaccinated <sup>†</sup>	20.5 [20.3-20.7]	8.31 [8.19-8.44]	5.34 [5.24-5.45]	1.81 [1.14-1.23]	0.95 [0.91-1.00]
<b>Effectiveness</b>					
BiBP-CorV	79.9% [79.4-80.4%]	72.6% [71.7-73.6%]	71.9% [70.7-73.1%]	85.3% [83.5-87.1%]	86.1% [84.1-88.0%]
ChAdOx1-S/nCoV-19	84.4% [83.5-85.3%]	79.4% [77.8-81.1%]	81.5% [79.5-83.4%]	89.5% [85.8-93.2%]	91.8% [88.2-95.4%]
rAd26-rAd5	74.7% [71.0-78.4%]	63.8% [57.0-70.6%]	67.5% [59.5-75.6%]	97.7% [93.1-100%]	100% [-] <sup>‡</sup>
BiV1-CovIran	87.1% [86.0-88.3%]	85.5% [83.6-87.4%]	86.4% [84.1-88.8%]	97.7% [95.7-99.7%]	98.3% [96.3-100%]

<sup>\*</sup> Suspicious = Negative RT-PCR but clinically in favor of COVID-19 infection; Definite = Positive RT-PCR and clinically in favor of COVID-19 infection.

<sup>†</sup> Incidence densities of the unvaccinated cohort for ChAdOx1-S/nCoV-19 vaccine were 22.36 [22.11-22.60], 9.25 [9.10-9.41], 5.94 [5.81-6.06], 0.92 [0.87-0.97], and 0.73 [0.69-0.78], respectively.

<sup>§</sup> 95% confidence interval

<sup>‡</sup> No mortality reported

Abbreviations: RT-PCR = reverse transcription–polymerase chain reaction.

433

434

435

436

437

438

439

440

441

442

443

444

445

446

**Table 3. SARS-CoV-2 vaccine effectiveness in different age groups**

Vaccine	Infection [Positive RT-PCR]	Hospitalization [suspicious/definite <sup>*</sup> ]	Hospitalization [definite]	Death [suspicious/definite]	Death [definite]
<b>BIBP-CorV</b>					
18-44 y	84.6% [83.8-85.3%] <sup>§</sup>	90.5% [89.3-91.6%]	86.2% [84.4-87.9%]	88.7% [82.1-95.1%]	87.3% [79.5-94.8%]
45-64 y	86.6% [86.0-87.2%]	91.0% [90.4-91.6%]	89.9% [89.1-90.7%]	97.2% [96.4-98.0%]	97.9% [97.1-98.7%]
>64 y	29.1% [25.3-32.8%]	55.4% [52.9-57.7%]	45.7% [42.1-49.2%]	86.1% [84.2-88.0%]	86.3% [84.1-88.4%]
<b>ChAdOx1-S/nCoV-19</b>					
18-44 y	74.6% [71.6-77.5%]	92.5% [89.5-95.4%]	93.5% [90.0-96.9%]	100% [-] <sup>‡</sup>	100% [-]
45-64 y	89.5% [87.9-91.2%]	94.6% [93.1-96.1%]	95.2% [93.4-97%]	99.1% [97.3-100%]	98.9% [96.7-100%]
>64 y	62.4% [59.0-65.6%]	77.0% [74.8-79.1%]	76.0% [73.0-78.9%]	95.6% [93.9-97.1%]	96.4% [94.7-98.0%]
<b>rAd26-rAd5</b>					
18-44 y	74.5% [70.0-78.9%]	58.4% [47.5-69.2%]	60.1% [46.9-73.4%]	100% [-]	100% [-]
45-64 y	78.2% [72.1-84.3%]	72.1% [63.1-81.1%]	76.0% [65.7-86.3%]	94.9% [84.9-100%]	100% [-]
>64 y	76.3% [53.1-99.5%]	28.7% [-7.5-64.8%]	45.5% [4.9-85.8%]	100% [-]	100% [-]
<b>BIV1-CovIran</b>					
18-44 y	89.7% [87.9-91.5%]	92.2% [89.2-95.2%]	94.4% [91.2-97.6%]	100% [-]	100% [-]
45-64 y	88.2% [86.8-89.6%]	89.8% [88.1-91.4%]	90.0% [87.9-92.0%]	98.6% [97.0-100%]	98.6% [97.3-100%]
>64 y	67.0% [58.5-75.4%]	78.4% [72.2-84.4%]	80.3% [72.8-87.8%]	97.6% [94.2-100%]	98.5% [95.5-100%]

<sup>\*</sup> Suspicious = Negative RT-PCR but clinically in favor of COVID-19 infection; Definite = Positive RT-PCR and clinically in favor of COVID-19 infection.

<sup>§</sup> 95% confidence interval

<sup>‡</sup> No mortality reported

Abbreviations: RT-PCR = reverse transcription–polymerase chain reaction.

447